The uptake of cholesterol carried by low-density lipoprotein (LDL) is tightly controlled in the body.
negative charges that render the Ox-LDL very attractive to macrophages in terms of uptake (phagocytosis) specially when aggregated in large particles as Agg-Ox-LDL 3 and are prevalent in atheromatous plaques. [4] [5] [6] [7] Monocytes differentiated into macrophages with M-CSF phagocytose aggregated, oxidized LDL (Agg-Ox-LDL) in large quantities. [5] [6] [7] This process is more prevalent in the arterial wall due to macrophage-secreted proteoglycan. 8 Macrophage foam cell formation requires Agg-Ox-LDL and neutralization of the cluster of differentiation CD36 (scavenger receptor) (CD36) receptor, in other words, is a process that involved CD36 receptor-mediated uptake of Ox-LDL. 9 The molecular and genetic mechanisms that govern macrophage phagocytosis of LDL and hasten inflammation are still unknown in terms of vascular biology. Until we understand these processes, therapeutic or surgical approaches used to disrupt/remove plaque will have suboptimal long-term outcomes, as the process of macrophage/foam cell formation will start again.
An underlying, chronic inflammation is responsible for the development and continued progression of atherosclerosis, 10 which is a significant health problem and a major contributor to cardiovascular disease (CVD). Atherosclerosis accounts for 1 in 3 deaths in the U.S., 11 continues to rise globally, [12] [13] [14] and is a major contributor to current healthcare costs. 11 Thus, it is very important to limit or terminate inflammation and start vascular healing early on. Plaque growth and swelling in a diseased artery involves migration of immune cells and the conversion of macrophages into foam cells. 15 Accumulation of
Ox-LDL in macrophage-derived foam cells directly affects foam cell migration and increases focal adhesion kinases (FAK), which drives
foam cell accumulation in the arterial intima leading to atheromatous plaque formation. 16 FAK signaling pathways heavily implicated in inflammation, cell migratory processes, and macrophage podosome and phagocytic cup formation include phospholipase D (PLD), Wiskott-Aldrich Syndrome protein (WASP) and Actin polymerization. [17] [18] [19] [20] [21] [22] PLD catalyzes the breakdown of the phospholipid phosphatidylcholine into phosphatidic acid (PA) and choline. 23, 24 PLD plays a key role in neutrophil and macrophage-initiated inflammation in many disease states, including chronic inflammation and CVD, due to its involvement in signaling pathways promoting cell growth, proliferation and migration. [25] [26] [27] Studies using PLD knockout (KO) mice or chemical inhibitors have reported that suppressing PLD is "protective" during ischemic stroke, 28 hypertension, 29 thrombosis, 30, 31 and myocardial infarction. 32 WASP has a poly-proline rich region, a polybasic region, and a GTPase Binding Domain and is a key regulator in the formation of phagocytic cups. [33] [34] [35] [36] [37] [38] [39] WASP binds to cofilin and the Arp2/3 complex through its C-terminal activity (verprolin-cofilinacidic) region to polymerize actin monomers (G-actin) into F-actin.
Previously, our laboratory showed that the phospholipase D2 isoform (PLD2) has a signaling role in WASP-mediated macrophage phagocytosis and phagocytic cup formation. 40 Defining a direct protein-protein interaction between PLD2-WASP in foam cells within the plaque is a novel approach that could potentially help to explain excessive phagocytosis of Ox-LDL.
In this study, we used either macrophages differentiated from PLD KO mice or the newest generation of PLD isoform-specific small molecule inhibitors 25, 28, 41 to inhibit macrophage foam cell phagocytosis. We report herein that macrophages phagocytose plaque cholesterol and undergo foam cell formation less efficiently in the absence of PLD2, suggesting a role for it in vivo in development of vascular inflammation and atheromatous plaques in the clinical setting. 
METHODS

Materials
RAW264.
Animals
Bone marrow-derived macrophages (BMDMs) were obtained from male or female wild-type (WT) (Charles River Laboratories, Charleston, SC). PLD1 −/− were generated at Dr. Yasunori Kanaho's laboratory, University of Tsukuba, Tennodai, Japan. 42 These PLD1-KO c57BL/6 mice had initially PLD2 in ES with exons 13 removed. 42 PLD2 −/− were generated at Dr. Gilbert Di Paolo's laboratory, Columbia University. 43 These PLD2-KO c57BL/6 mice had initially PLD2 in ES with exons 13-15 removed. 43 WT mice were also in the C57Bl/6 background at 6-8 weeks of age (weighing 20-25 g) comparable to the KOs. The mice were provided a temperature-and light-controlled environment with unrestricted access to food (laboratory standard rodent diet 5001 (Laboratory Diet, St. Louis, MO)) and water. The mice had veterinary care, were checked every day, and experiments were performed in accordance with the Wright State University (WSU) Institutional Animal Care and Use Committee (IACUC) guidelines.
Experiments for this manuscript have also followed the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978).
Isolation of BMDMs
Bone marrow from WT, PLD1 −/− , and PLD2 −/− euthanized mice was extracted from femurs and tibias according to. 44 The bones were washed once in 70% ethanol and then twice in 1× PBS. The epiphyses (ends of the femur and tibia) were cut carefully with a new, single-edge razor, and then, using a 12 cc syringe and 25 G × 5/8 in. needle, RPMI media with 10% FBS and 2 mM EDTA was used to flush out the bone marrow cells, which were passed through a 100 mm cell strainer placed on top of a 50 ml conical tube. This step was repeated from the other end of the bone to obtain the maximum number of cells possible. The bones were then cut into pieces, placed on top of the cell strainer, and crushed with the back of the syringe to recover any remaining cells.
The cells were then sedimented at 1400 rpm for 7 min at 4 • C, resuspended in 1× PBS, and counted. Cells were allowed to settle in the centrifuge tube and then the supernatant media carefully aspirated. The cells were resuspended in 20 ml of 0.2% NaCl to lyse red blood cells and incubated for 20 s. Twenty milliliters of 1.6% NaCl was then added and the cells sedimented at 1400 rpm for 7 min at 4 • C. The pellet was resuspended in 1 ml RPMI media with 10% FBS and 2 mM EDTA, centrifuged at 1400 rpm for 7 min at 4 • C, and resuspended in 1 ml of RPMI media with 10% FBS and 100 ng/ml M-CSF.
Differentiation of bone marrow cells into BMDM
Bone marrow cells were plated at a density of 2.0-2.5 × 10 7 cells/plate in 100 mm tissue culture-grade plates. Media was changed on Day 3 and again on Day 6 with RPMI-1640, 10% FBS, Pen-Strep, and 100 ng/ml M-CSF. On Day 7, the BMDMs were washed twice with PBS and harvested by incubation in 10 ml PBS containing 10 mM EDTA, followed by vigorous pipetting using complete RPMI media with 100 ng/ml M-CSF. The BMDMs were sedimented at 250xg for 5 min and counted using a hemocytometer.
Preparation of Agg-Ox-LDL
Extensively oxidized LDL can interact with phagocytic cells 45, 46 leading to delivery of LDL to macrophages by phagocytosis and subsequent formation of foam cells. 47 LDL aggregation and fusion are important early steps in atherogenesis. 48 As LDL oxidation increases aggregation, [49] [50] [51] we used 20 M copper-highly oxidized LDL (cat. # L34357) from Life Technologies at an initial concentration of 1 mg/ml. Extent of aggregation was monitored by absorbance (turbidity) at 680 nm before each experiment. However, physical properties of AggOx-LDL were measured initially for each batch in a NanoSight NS300 with a 405 nm laser instrument (Malvern Instruments, Malvern, UK). A typical measurement indicated that the mean size of the particles was 138 ± 6.0 nm and 90% of the particles had sizes of 212 ± 1.2 nm or below. Since size of single-molecule, nonoxidized LDL is only ∼20 nm, we call our preparations for the experiments "aggregated, oxidized LDL" (Agg-Ox-LDL).
Phagocytosis of Agg-Ox-LDL by macrophage foam cells
BMDMs from c57BL/6 mice or were differentiated into macrophages by continuous culture with 100 ng/ml M-CSF. 52 RAW264.7 macrophages were incubated as we have described in Refs. 25-27. Cells were plated in a 12-well plate at a density of 2.5 × 10 5 cells/well and allowed to grow overnight in a humidified 37 • C incubator. AggOx-LDL were added to the wells (0, 50, or 100 g/ml) for 24 or 48 h after which the media was aspirated and the cells washed in 1× PBS.
Foam cells were fixed in 4% paraformaldehyde, washed with 1× PBS, and then incubated twice with 1 ml of 100% propylene glycol for 5 min each time. The supernatants were aspirated and the cells stained with 1 ml of 65 • C Oil Red O for 1 h. The stain was aspirated and the cells washed with 85% propylene glycol for 3 min followed by 2× in distilled water. The cells were counter-stained using hematoxylin for 2 min and washed 7× with water. After air drying, photomicroscopic imaging was conducted using an EVOS microscope (40× magnification). Oil
Red O-stained foam cells were quantified in terms of fold-difference compared with control samples. 4, 7 Foam cell formation was measured using Image J. The bright-field images were opened and scale was set to 200 m. The images were then set to grayscale using RGB stack, with threshold set to half the maximum threshold. The images were then analyzed by clicking measure to obtain the intensity of oil red staining. 53 
Phagocytosis of zymosan
Macrophage phagocytosis was performed as per prior studies. 40, 54 Briefly, phagocytosis was measured using phRhodo Red zymosan (Life 
Immunofluorescence microscopy of phagocytosis key proteins
Macrophage foam cells were incubated with Agg-Ox-LDL in a timecourse experiment to measure phagocytic cup formation, similar to. 40 Samples were fixed, permeabilized, blocked and then incubated with fluorescent antibodies specific to WASP, growth factor receptorbound protein 2 (Grb2), and PLD2 using AlexaFluor350-, FITC-, or tetramethylrhodamine isothiocyanate (TRITC) labeling of 2 out of the 3 total proteins at any one time, allowing us to visualize fluorescent Agg-Ox-LDL and 2 target proteins. 40, 55 Photomicrographs at 100x magnification were rendered using a Nikon Eclipse 50i inverted fluorescence microscope, Infinity2 Lumenera digital camera and Infinity Analyze software (v. 6.2). The immunofluorescence colocalization of protein pairs was quantified using ImageJ software with ∼2-4 cells per field; 6 fields; n = 3 independent experiments, by determining the Pearson's coefficient, 56, 57 which was then plotted as % of colocalization (yellow = TRITC-PLD2 and FITC-Grb2; or TRITC-PLD2 and FITC-Actin; or TRITC-PLD2 and FITC-WASP). 
Human artery specimens
Gene expression measurement
Relative mRNA gene expression levels were measured by quan- 
Computational transcriptomic analysis
For the data presented in Fig. 1 , we used gene expression data from the human carotid artery atheroma study included in the NCBI Gene Expression Omnibus (GEO) microarray dataset. 58 We chose this study as it included carotid artery atheromatous plaque samples from hypertensive human patients compared with control companion healthy artery tissue. We used data from a single study to assure that it was generated using similar methodologies. The study we chose had 34 pairs of normal, adjacent carotid tissue and atheroma plaque. Per Ayari and Bricca, 58 gene expression values were scaled logarithmically. All of the data from the genes of interest were downloaded to MS Excel spreadsheets from GEO during July 2016. Genes were defined as being overexpressed or underexpressed when the fold-change in the atheroma plaque group was significantly different compared with the adjacent normal carotid tissue (P < 0.05). Results were analyzed using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA). Unpaired ttests were used to compare gene expression data.
PLD inhibitors
The PLD inhibitors VU0155069 (selective for PLD1), that has an IC 50 of 9 nM, 59 VU0364739 (also called NFOT; selective for PLD2) that has an IC 50 of 10 nM, 59 and FIPI (a dual PLD1/2 inhibitor) 60 that has an IC 50 of 10 nM for PLD1 and 8 nM for PLD2, 59 were added to the cell cultures at 700 nM for 30 min prior to initiating experiments. We studied the effect of PLD inhibitors on foam cell formation after 24 h by Oil-red O staining.
SDS-PAGE and Western blot analyses
To confirm the presence of the proteins of interest in the human artery samples, we performed SDS-PAGE and Western blot analyses specific for these proteins, as well as for actin as a protein load- After incubation, the immunoprecipitates were washed with LiCl wash buffer (2.1% LiCl, 1.6% Tris-HCl, pH 7.4) and NaCl wash buffer 
Coimmunoprecipitation
analyzed using SDS-PAGE and Western blotting (WB).
Statistical analysis
Data presented in the figures as bars are means + SEM (SD/n1/2, were n is the sample size). Experiments were performed in technical triplicates (for qPCR assays) or technical duplicates (for PLD activity assays) for n = 5 independent experiments. The difference between means was assessed by the single factor ANOVA test or paired t-test, calculated using Prism 7 (GraphPad Software Inc., La Jolla, CA). Probability of P < 0.05 indicates a significant difference. In the figures, the (*) symbols above bars denote statistically significant (P < 0.05) ANOVA or ttest increase or decrease between samples and controls.
RESULTS
Macrophage phagocytosis of Agg-Ox-LDL is reduced in the absence of PLD2 activity
Based on earlier work from our laboratory that outlined the impor- Bone marrow-derived monocytes from WT and PLD1-and PLD2-deficient mice were differentiated into macrophages 52 and then stimulated to undergo foam cell formation by incubation with 50 g/ml aggregated, oxidized LDL (Agg-Ox-LDL) cholesterol. 50, 63 We used BMDMs because they are uniformly quiescent until stimulated, whereas intraperitoneal macrophages are activated to varying levels.
Foam cell formation was monitored by staining for macrophage internalization of Agg-Ox-LDL using Oil Red O, a fat-soluble dye that binds to neutral triglycerides and lipids. 64, 65 Foam cells have an enlarged, red appearance in comparison with the relatively smaller, pale-colored macrophages (Fig. 1B) . WT and PLD1 −/− macrophages both readily took up Agg-Ox-LDL and formed foam cells to similar extents as determined by visual inspection (Fig. 1C) and were not significantly different in uptake based on quantitation (Fig. 1D) . In contrast, PLD2 −/− macrophages phagocytosed significantly less Agg-Ox-LDL compared with WT mice and formed foam cells at a reduced frequency over the time-course of the assay (Figs. 1C and 1D) . Data in Fig. 1D indicate that the absence of PLD1 provokes a reduction of ∼27% in phagocytosis (compared with WT), whereas the absence of PLD2 provokes a reduction of >60%. Since the reduction in the first case was small and within the margin of SEM of WT, we considered the involvement of PLD2 as more robust.
Further, we believe that the physiologic reason for a larger participation of PLD2 is because this isoform has been found in the plasma membrane 66 and cytosol, whereas PLD1 is localized in the ER and Golgi membranes. 67 Thus, PLD2 would appear to be more important for cytoskeletal rearrangements during active phagocytosis of Ox-LDL as it is localized at the plasma membrane.
For controls of macrophage phagocytosis, we performed experiments where BMDMs from WT, PLD1-KO, or PLD2-KO were presented with phRhodo Zymosan for phagocytosis. Fig. 1E indicates a reduced rate of phagocytosis when PLD2 isoform is knocked out. This is in line with well-known results of regulated macrophage phagocytosis. Thus, while BMDMs needed both PLD1 and PLD2 for general phagocytosis, those cells relied heavily on PLD2 to mediate phagocytosis of Agg-Ox-LDL for formation of foam cells, which is a novel result presented herein.
PLD inhibitors reduce Agg-Ox-LDL phagocytosis
PLD2 interacts with many different proteins and has been proposed in some contexts to have noncatalytic roles. 68 To address whether PLD activity is key for Agg-Ox-LDL phagocytosis, we investigated the ability of small molecule PLD inhibitors to reduce Agg-Ox-LDL uptake from macrophages. WT macrophages were cultured in media containing inhibitors that block activity of both PLD1 and PLD2 (FIPI), 60 and relatively selective for PLD1 (VU0155069), 26, 69 or selective for PLD2 (VU0364739). Agg-Ox-LDL uptake by macrophages was significantly inhibited by all 3 inhibitors, with the PLD2-selective inhibitor (VU0364739) being the most potent and the PLD1-selective inhibitor (VU0155069) being the least potent ( Fig. 2A) . At 700 nM VU0155069, the highest concentration that significantly inhibited uptake (data not shown), PLD2 is also partially inhibited, 69 suggesting that PLD1 may have a weak if any role in the phagocytosis observed.
To test if Agg-Ox-LDL phagocytosis had any component mediated by scavenger receptor CD36, [70] [71] [72] which signals through Src and Jnk2, [73] [74] [75] we generated BMDMs from WT, PLD1, and PLD2 mice and blocked CD36 using a monoclonal Ab during culture of the cells with Agg-Ox-LDL. The CD36 Ab was effective in reducing Agg-Ox-LDL uptake for WT and PLD1 −/− BMDMs. Blocking CD36 in WT and PLD1-KO (in both cases PLD2 is still present), ingestion of Ox-LDL was reduced to levels equivalent to PLD2-KO, indicating that CD36 is needed for the clearance of 3 particles. However, CD36 antibodies did not reduce uptake by PLD2 −/− BMDMs beyond the suppression already created by the absence of PLD2 (Fig. 2B) . Thus, in the absence of PLD2, CD36 does not seem to engage in ox-LDL removal. Additionally, whatever low level of uptake was observed in PLD2-KO cells (putatively due to PLD1 or other pathways) was found further reduced when the cells were incubated with cytochalasin D (Fig. 2B) , a well-known cytoskeleton disruptor and phagocytosis inhibitor. Both these results (anti-CD36 Ab and cytochalasin D), along with the fact that we used in the experiments Agg-Ox-LDL (particles ∼10× larger in diameter than individual LDL molecules) indicate that the uptake occurred through 
The heterotrimeric protein complex of PLD2-Grb2-WASP
PLD2, through its product PA, mediates cell migration of macrophages and neutrophils. 76, 77 This signaling pathway is also dependent on WASP (a crucial protein needed for actin polymerization and, as such for phagocytosis) and on Grb2, with Grb2 functioning as the docking protein that mediates the physical interaction between PLD2 and WASP (Fig. 3A) . The SH2 domain of Grb2 interacts with the Y169 and Y179 residues of PLD2, whereas the 2 SH3 domains of Grb2 interact with the polyproline region of WASP. This heterotrimeric protein binding interaction is dependent on PA (dioleoyl-PA), as macrophages incubated in the presence of 300 nM dioleoyl-PA exhibited increased interaction of PLD2-Grb2-WASP as a function of time, as shown using coimmunoprecipitation (Fig. 3B) . A recent study has shown that exogenously supplied PA can be detected by a PA sensor inside cells during phagocytosis. 78 Moreover, from previous studies in our laboratory, we know that exogenously supplied PA activates PLD (to mimic activated PLD), resulting in increased activity and downstream cellular signaling cascades. 79, 80 To investigate whether the same proteins are involved in Agg-Ox-LDL phagocytosis by macrophages, we used 50 g/ml Agg-Ox-LDL to induce BMDM cells to form foam cells and performed immunofluorescent immunostaining to visualize PLD2, Grb2, WASP, and Actin localization. The results are broken in the study of interactions of 2 proteins at the time. We first asked if a Grb2-PLD2 interaction could be detected in IF as it was in IP/WB (Fig. 3B) . As presented in Fig.s 3C and 3D, in the absence of Agg-Ox-LDL in the cell cultures, Grb2 and PLD2 did not visually colocalize. In Fig. 3C , the red (PLD2-TRITC) and Macrophages were treated with 300 nM phosphatidic acid (dioleoyl-PA) for 0, 7, or 14 min. Cell lysates were immunoprecipitated using Protein-G agarose linked to antibodies specific for PLD2, WASP, or Grb2 and used for SDS-PAGE. Detection of the protein-protein interactions on subsequent Western blots using a 2 protein approach indicates protein-protein interaction occurred between PLD2 and WASP, between PLD2 and Grb2 and between WASP and Grb2, which suggests formation of a protein heterotrimeric complex (PLD2-Grb2-WASp) in the presence of PA (i.e., in conditions where PLD2 would be activated). (C) BMDMs with or without 50 g/ml oxLDL treatment were subject to immuno-staining with TRITC-PLD2 and FITC-Grb2. Scale bar, 50 m. Red and green arrowheads point at regions where staining is separated, whereas white arrows point at areas where there is signal colocalization. 
Arterial gene expression during atherosclerosis
To pursue clinical correlates, we mined gene expression profiles of PLD and some of its key signaling protein partners in a human disease that relies heavily on macrophage function and signaling. Through comparing relative mRNA expression levels in human atheroma plaque tissue and adjacent, nondiseased carotid artery samples, using the F I G U R E 5 Bioinformatic analysis of PLD and its signaling proteins in human atheroma plaque tissues. Microarray data were from the NCBI Gene Expression Omnibus (GEO) and specifically from the carotid artery atheroma dataset. 58 (A-E) NF (P = 0.0016) (used here as a proxis for inflammation), PLD2 (P = 0.005), Grb2 (P < 0.0001) and WASP (P < 0.0001) are significantly up-regulated in diseased atheroma plaques, whereas PLD1 is not (P = 0.2432). The symbols * denote statistically significant (P < 0.05) increases between atheroma plaque and control adjacent carotid artery samples Carotid Artery Atheroma Dataset at the GEO microarray (accession number GDS5083), 58 we determined that NF B1 (used here as a general marker of inflammation), PLD2, WASP, and Grb2 (P = 0.0016, P = 0.005, and P < 0.0001, respectively) undergo up-regulation in diseased vascular tissue (Figs. 5A-5D ). NFkb1 represented a positive control, as it is a well-known marker of inflammation. In contrast, there was no change in expression of PLD1 (Fig. 5E , P = 0.24), further supporting its lack of relevance in context of this disease. 
PLD2 but not PLD1 is up-regulated in diseased artery tissues-A translational study
To confirm that hypoxic conditions actually do trigger PLD expression in diseased human artery and atheromatous plaques, we used human undamaged control and diseased atherosclerotic artery specimens to assess both relative mRNA and protein expression levels. We performed quantitative RT-PCR and/or SDS-PAGE/Western blot analyses on human patient samples and measured the expression levels of PLD, Grb2, and WASP. We analyzed samples for both PLD isoforms and found that although PLD2 mRNA was significantly up-regulated in the diseased artery and plaque samples (Fig. 6A) , PLD1 mRNA was (Fig. 6B ). Similar findings were observed for PLD2 and PLD1 protein expression levels by Western blot (Fig. 6C) ;
PLD2 was up-regulated in the diseased artery samples that contained atherosclerotic plaque (both from diseased femoral artery and ileofemoral endarterectomy), whereas PLD1 was down-regulated.
Up-regulation of WASP and Grb2 in diseased artery tissues
We similarly investigated the expression of WASP and Grb2 in human undamaged control and diseased atherosclerotic artery specimens.
WASP and Grb2 protein expression levels were increased in the diseased artery samples compared with the nondiseased companion tissues (Figs. 6C and 6D ). Furthermore, WASP activation was increased, as assessed by detecting phosphorylation at the WASP tyrosine residue 290, using a phosphotyrosine-specific Ab (Figs. 6C and   6D ). These data suggest a role for activation of WASP protein in the diseased artery and plaque samples, which could play a role in membraneassociated actin polymerization at the leading edge of phagocytic arms involved in phagocytosis of Agg-Ox-LDL and foam cell formation. (Fig. 7B ).
Validation of PLD2, WASP, and Grb2 in diseased human artery samples
In contrast, immunofluorescence staining of these tissues using rabbit -PLD2-FITC-conjugated IgG antibodies indicated that PLD2 expression is concentrated in the plaque in diseased arteries (Fig. 7C) and in the plaque that was removed during endarterectomy when compared with the diseased artery alone. The positive PLD2 staining in the diseased artery (Fig. 7C , left panel) appears to be towards the lumen.
The positive staining in the plaque (Fig. 7C , middle panel), appears to be adjacent to the staining in the diseased artery. Thus, PLD2 appears in the area of the plaque underneath the fibrous cap. We identified that PLD2 makes macrophage phagocytose Agg-Ox-LDL to form foam cells more efficiently in a process that is dependent on mechanism of PLD-Grb2-WASP interaction. Other studies have shown that PLD2 regulates RGS2 expression in foam cell formation, 87 but a direct role of PLD in foam cell formation has not been shown to date.
DISCUSSION
We also know from previous studies that PLD2 plays an important role in receptor endocytosis. 88 Our study reveals that PLD2 not only regulates macrophage phagocytosis by phagocytic cup formation, but also promotes phagocytosis of Agg-Ox-LDL via CD36 (a Class B scavenger receptor). In line with previous studies emphasizing the role of PLD2
in receptor endocytosis, we found that in the absence of PLD2, CD36
mediated Agg-Ox-LDL uptake by macrophages during foam cell formation is negatively affected.
The data presented in this study support a key role for PLD2, as PLD2 −/− macrophages phagocytose aggregated Ox-LDL (Figs. 1C and 1D) less efficiently than PLD1 −/− macrophages and PLD2-specific inhibitors diminish phagocytosis of Agg-Ox-LDL ( Fig. 2A) . Gene and protein expression from diseased human artery and plaque samples indicate PLD2 but not PLD1 correlates with diseased vessels (Fig. 6) .
Thus, we have demonstrated that PLD2 plays a role in macrophage during foam cell formation, whereas PLD1 does only marginally.
WASP is linked with actin polymerization, and we show that phospho-WASP is present in the atheromatous plaque removed during ileofemoral endarterectomy from diseased arterial samples (Fig. 6 ).
Likewise, we also observed that PLD2 and Grb2 were up-regulated in the diseased artery/plaque samples with very low basal expression in nondiseases artery (Fig. 6) . We also know from other studies in the lab that hypoxia promotes macrophage PLD activity (data not shown).
Based on this, we propose that once activated by hypoxia, PLD hastens the phagocytic capability of foam cells through a mechanism that involves PLD2-Grb2-WASp interaction and subsequent actin remodeling to form phagocytic cups for Ox-LDL uptake by macrophages and consequently foam cell formation (Fig. 8) .
Overall, we present a new paradigm: that CD36-PLD2-Grb2-WASP heterotrimeric signaling axis in macrophages is a key mediator of macrophage phagocytosis of Agg-Ox-LDL and subsequent foam cell formation, as indicated in the model presented in Fig. 8 . We hypothesize that a mechanism for specific coupling between Agg-oxLDL and PLD2 could involve the negative curvature of PA in phagocytic arms or extensions of the phagocytic cup, that accounts for enhanced PLD activity and thus its role in CD36 uptake of Agg-Ox-LDL via receptor endocytosis. PLD is known for its role in inducing membrane curvature during leukocyte migration and phagocytosis 40, 89 as well as receptor endocytosis. 66, 88 This knowledge of a CD36-PLD2-Grb2-WASP heterotrimeric signaling axis provides specific new protein targets in vascular biology that have potential implications for improving human health. The proposal that elevated PLD2, Grb2, and WASP expression/activation may support progression of the atherosclerosis is significant, as potent, new small-molecule inhibitors are currently available that could be used to pharmacologically inhibit foam cell formation.
According to the present study, using the PLD1-KO and PLD2-KO mice from references 42 and 43, respectively, the PLD2 −/− macrophages do not take up Agg-Ox-LDL as well as WT macrophages do. However, it is entirely possible that they would eventually (meaning 
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